Greater efficacy of PARP inhibition has been observed in earlier lines of therapy, with olaparib trials for both breast cancer (OlympiA vs OlympiAD trials6,7) and ovarian cancer (SOLO1 vs SOLO2 trials8,9). This evidence concerns the gene PARP1 and breast carcinoma.